Company Profile: Renovion, Inc.

CED Life Science Conference 2017 - Lightning Round                                                            
Sub-sector: Biotech and Pharmaceutical                                                               
Year Founded: 2013

Renovion, Inc. is a pre-clinical stage company with more than 15 years of human safety and efficacy experience with our lead compound: Arina-1. Our goal is to be the first FDA-approved medication for lung transplant patients. After success in this population, we will pursue approval in in cystic fibrosis, asthma and other potential patient populations, such as COPD. The initial patent is licensed from UNC and Renovion filed two additional provisional patents in Q4 2016. The compound is nebulized 2x day and shows both anti-inflammatory and antimicrobial effect evidenced by in vitro and in vivo research. The compound impacts growth of anaerobic bacteria via the nitric oxide pathway. In antimicrobial research completed in Q4 2016, delivered dose concentrations of Arina-1 inhibited growth of 12 bacteria tested, including Pseudomonas aeruginosa, Burkholderia cepacia and MRSA. These findings support the observed clinical outcomes.

Dan Copeland, Chief Executive Officer
Carolyn Durham, Chief Development Officer


  • Funding: Seed Funding: $1.7MM Kickstart Venture Award, $50k Current Series A Round seeking $8MM to fund through NDA submission in Q1 2019
  • Seed round completion
  • Selected to present in Washington DC at University Start Up/Demo Day
  • Kickstart Venture Award Innovate Carolina

Carolina KickStart, Innovate Carolina, NC Biotechnology Center, NCBIO, UNC Chapel Hill Office of Technology Development

Dan Copeland
Durham, NC

Learn more about the CED Life Science Conference.